Annual Report 2025

Share this page

Creating tomorrow’s solutions

Share this page

Services

Download Center Key-Figures Comparison Sites GRI Index TCFD Index

Consolidated Segment Information by Division

January 1 to December 31

€ million

 

Silicones

 

Polymers

 

Biosolutions

 

Polysilicon

 

Other

 

Consolidation

 

Group

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External sales

 

2,733.0

 

1,367.3

 

360.4

 

882.4

 

142.2

 

–

 

5,485.3

Internal sales

 

0.2

 

11.2

 

–

 

0.5

 

–

 

-11.9

 

–

Total sales

 

2,733.2

 

1,378.5

 

360.4

 

882.9

 

142.2

 

-11.9

 

5,485.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT1

 

180.2

 

94.1

 

-122.6

 

-51.2

 

-280.8

 

0.6

 

-179.7

Depreciation/amortization

 

155.5

 

64.2

 

143.3

 

147.4

 

96.0

 

–

 

606.4

EBITDA1

 

335.7

 

158.3

 

20.7

 

96.2

 

-184.8

 

0.6

 

426.7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIt includes: restrucuring costs

 

–

 

–

 

–

 

–

 

-102.6

 

–

 

-102.6

result from investments in joint ventures and associates

 

2.3

 

–

 

–

 

–

 

-337.0

 

–

 

-334.7

therefore Impairment of investment in associates

 

–

 

–

 

–

 

–

 

-307.8

 

–

 

-307.8

Impairment of fixed assets

 

5.7

 

5.2

 

91.4

 

–

 

–

 

–

 

102.3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset additions2,3

 

201.9

 

55.2

 

26.3

 

96.3

 

86.2

 

–

 

465.9

Additions to financial assets

 

–

 

–

 

–

 

–

 

0.7

 

–

 

0.7

Asset additions

 

201.9

 

55.2

 

26.3

 

96.3

 

86.9

 

–

 

466.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets (Dec. 31)

 

2,479.1

 

883.0

 

612.1

 

1,123.5

 

3,273.9

 

-0.6

 

8,371.0

Liabilities (Dec. 31)

 

1,193.7

 

443.0

 

240.7

 

726.2

 

2,012.1

 

-0.3

 

4,615.4

Net assets (Dec. 31)

 

1,285.4

 

440.0

 

371.4

 

397.3

 

1,261.8

 

-0.3

 

3,755.6

Investments in joint ventures and associates included in net assets (Dec. 31)

 

82.0

 

–

 

–

 

–

 

517.2

 

–

 

599.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

79.6

 

37.0

 

7.5

 

49.6

 

40.9

 

–

 

214.6

Employees (Dec. 31)

 

6,235

 

1,612

 

1,127

 

2,349

 

5,144

 

–

 

16,467

Employees (average)

 

6,262

 

1,626

 

1,165

 

2,370

 

5,193

 

–

 

16,616

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

External sales

 

2,805.2

 

1,448.5

 

374.9

 

949.2

 

144.0

 

–

 

5,721.8

Internal sales

 

0.1

 

14.8

 

–

 

–

 

–

 

-14.9

 

–

Total sales

 

2,805.3

 

1,463.3

 

374.9

 

949.2

 

144.0

 

-14.9

 

5,721.8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT1

 

197.0

 

136.0

 

-17.1

 

70.0

 

-114.3

 

-0.7

 

270.9

Depreciation/amortization

 

143.9

 

58.4

 

52.2

 

123.4

 

94.8

 

–

 

472.7

EBITDA1

 

340.9

 

194.4

 

35.1

 

193.4

 

-19.5

 

-0.7

 

743.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBIT includes: restructuring costs

 

–

 

–

 

–

 

–

 

–

 

–

 

–

Result from investments in joint ventures and associates

 

6.3

 

–

 

–

 

–

 

12.8

 

–

 

19.1

thereof Impairment of investments in associates

 

–

 

–

 

–

 

–

 

–

 

–

 

–

Impairment of fixed assets

 

0.8

 

–

 

9.2

 

–

 

–

 

–

 

10.0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset additions2,3

 

266.3

 

75.4

 

49.3

 

199.7

 

118.7

 

–

 

709.4

Additions to financial assets

 

–

 

–

 

–

 

–

 

0.5

 

–

 

0.5

Asset additions

 

266.3

 

75.4

 

49.3

 

199.7

 

119.2

 

–

 

709.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets (Dec. 31)

 

2,698.6

 

941.7

 

759.7

 

1,259.8

 

3,750.5

 

-0.4

 

9,409.9

Liabilities (Dec. 31)

 

1,200.8

 

426.1

 

234.4

 

778.8

 

1,932.8

 

–

 

4,572.9

Net assets (Dec. 31)

 

1,497.8

 

515.6

 

525.3

 

481.0

 

1,817.7

 

-0.4

 

4,837.0

Investments in joint ventures and associates included in net assets (Dec. 31)

 

92.7

 

–

 

–

 

–

 

883.5

 

–

 

976.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

77.2

 

34.3

 

9.6

 

40.8

 

41.8

 

–

 

203.7

Employees (Dec. 31)

 

6,242

 

1,613

 

1,189

 

2,375

 

5,218

 

–

 

16,637

Employees (average)

 

6,167

 

1,607

 

1,187

 

2,352

 

5,207

 

–

 

16,520

1

Investments in joint ventures and associates and other income from investments reclassified to other financial result (expense of €329.7 million; prior year: €19.2 million in income); EBITDA and EBIT were adjusted accordingly. Further details can be found in the section “Changes in accounting policies”.

2

Intangible assets; property, plant and equipment; investment property; excluding right-of-use assets. The segment information by division is an integral part of the Notes to the consolidated financial statements. For explanations of the key indicators, see Note 22.

3

Due to a change in accounting policy, emission certificates are presented under intangible assets (€11.5 million; prior year: €43.4 million). Previously, they were presented under inventories. Further details can be found in the section “Changes in accounting policies”.

Related topics